/// The Threat ///

Pressure From Two Fronts

American biopharmaceutical leadership is under pressure from two directions at once. Predatory statecraft abroad. Policy erosion at home. Eight pressure points press on the same base, each one documented.

+ Select any pressure point › read the brief and its source
Front 01 Abroad Predatory statecraft
U.S. Biopharmaceutical Base
Under Pressure
Front 02 At Home Policy erosion
/// Brief
Eight Pressure Points

Four from abroad, four at home. Select any one above to open its full brief: the threat, how it works, why it matters, and the source behind the numbers.

/// Where This Leaves Us ///

The Pressure Compounds

Neither front tells the whole story. Predatory statecraft abroad and policy erosion at home are running at the same time, and they feed each other. A weaker base at home is easier to outpace from abroad. A stronger rival abroad makes every cut at home cost more.

None of this moves on a political calendar. Research lost takes a decade to rebuild. Talent that leaves does not return on command. A supply chain concentrates over years and cannot be restored in a season. The lead compounds for whoever holds it, which is why the time to answer is now.

The threat is documented. What comes next is a choice, and not every answer helps. Some responses cut more than they protect.

7,100
Clinical trials China listed in 2024, ahead of the U.S. at roughly 6,000.
ITIF / WHO registry
~80%
Of active pharmaceutical ingredients are sourced abroad, by production volume.
U.S. FDA
43%
Of U.S. doctorate-level scientists and engineers are foreign-born.
National Science Board
$2.45B
In NIH grants terminated between February and August 2025.
PNAS
Naming the threat is the easy part. The damage comes from the answer.
/// The Response ///
Now Weigh It

Every answer carries trade-offs, and not all of them help. Pick the policies, see the consequences, and find the mix that gets the base ahead.

Enter the Simulation › A policy simulation // Keep America Competitive and Secure